These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 25982284

  • 1. Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia.
    Flores-Castillo C, Zamora-Pérez JÁ, Carreón-Torres E, Arzola-Paniagua A, Aguilar-Salinas C, López-Olmos V, Fragoso JM, Luna-Luna M, Rodríguez-Pérez JM, Franco M, Vargas-Alarcón G, Pérez-Méndez Ó.
    Fundam Clin Pharmacol; 2015 Aug; 29(4):362-70. PubMed ID: 25982284
    [Abstract] [Full Text] [Related]

  • 2. Atorvastatin and Fenofibrate Increase the Content of Unsaturated Acyl Chains in HDL and Modify In Vivo Kinetics of HDL-Cholesteryl Esters in New Zealand White Rabbits.
    Flores-Castillo C, Luna-Luna M, Carreón-Torres E, López-Olmos V, Frías S, Juárez-Oropeza MA, Franco M, Fragoso JM, Vargas-Alarcón G, Pérez-Méndez Ó.
    Int J Mol Sci; 2019 May 22; 20(10):. PubMed ID: 31121898
    [Abstract] [Full Text] [Related]

  • 3. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    Nissen SE, Nicholls SJ, Wolski K, Howey DC, McErlean E, Wang MD, Gomez EV, Russo JM.
    JAMA; 2007 Mar 28; 297(12):1362-73. PubMed ID: 17384435
    [Abstract] [Full Text] [Related]

  • 4. Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates.
    Carreón-Torres E, Rendón-Sauer K, Monter-Garrido M, Toledo-Ibelles P, Gamboa R, Menjivar M, López-Marure R, Luc G, Fievet C, Cruz D, Vargas-Alarcón G, Pérez-Méndez O.
    Clin Chim Acta; 2009 Mar 28; 401(1-2):37-41. PubMed ID: 19036342
    [Abstract] [Full Text] [Related]

  • 5. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
    Kurogi K, Sugiyama S, Sakamoto K, Tayama S, Nakamura S, Biwa T, Matsui K, Ogawa H, COMPACT-CAD Investigators.
    J Cardiol; 2013 Aug 28; 62(2):87-94. PubMed ID: 23672789
    [Abstract] [Full Text] [Related]

  • 6. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
    Lemieux I, Salomon H, Després JP.
    Ann Med; 2003 Aug 28; 35(6):442-8. PubMed ID: 14572169
    [Abstract] [Full Text] [Related]

  • 7. Normal HDL-apo AI turnover and cholesterol enrichment of HDL subclasses in New Zealand rabbits with partial nephrectomy.
    Toledo-Ibelles P, Franco M, Carreón-Torres E, Luc G, Tailleux A, Vargas-Alarcón G, Fragoso JM, Aguilar-Salinas C, Luna-Luna M, Pérez-Méndez O.
    Metabolism; 2013 Apr 28; 62(4):492-8. PubMed ID: 23089050
    [Abstract] [Full Text] [Related]

  • 8. Hyperuricemia is Associated with Increased Apo AI Fractional Catabolic Rates and Dysfunctional HDL in New Zealand Rabbits.
    Martínez-Ramírez M, Flores-Castillo C, Sánchez-Lozada LG, Bautista-Pérez R, Carreón-Torres E, Fragoso JM, Rodriguez-Pérez JM, García-Arroyo FE, López-Olmos V, Luna-Luna M, Vargas-Alarcón G, Franco M, Pérez-Méndez O.
    Lipids; 2017 Dec 28; 52(12):999-1006. PubMed ID: 28940111
    [Abstract] [Full Text] [Related]

  • 9. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR, Crouse JR, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB, Simvastatin Atorvastatin HDL Study Group.
    Curr Med Res Opin; 2001 Dec 28; 17(1):43-50. PubMed ID: 11464446
    [Abstract] [Full Text] [Related]

  • 10. Atorvastatin and Fenofibrate Exert Opposite Effects on the Vascularization and Characteristics of Visceral Adipose Tissue in New Zealand White Rabbits.
    Mondragón-García A, Luna-Luna M, Flores-Castillo C, Aranda-Fraustro A, Carreón-Torres E, López-Olmos V, Fragoso JM, Vargas-Alarcón G, Pérez-Méndez Ó.
    J Cardiovasc Pharmacol Ther; 2019 Nov 28; 24(6):559-566. PubMed ID: 31056933
    [Abstract] [Full Text] [Related]

  • 11. Increased HDL Size and Enhanced Apo A-I Catabolic Rates Are Associated With Doxorubicin-Induced Proteinuria in New Zealand White Rabbits.
    López-Olmos V, Carreón-Torres E, Luna-Luna M, Flores-Castillo C, Martínez-Ramírez M, Bautista-Pérez R, Franco M, Sandoval-Zárate J, Roldán FJ, Aranda-Fraustro A, Soria-Castro E, Muñoz-Vega M, Fragoso JM, Vargas-Alarcón G, Pérez-Méndez O.
    Lipids; 2016 Mar 28; 51(3):311-20. PubMed ID: 26781765
    [Abstract] [Full Text] [Related]

  • 12. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.
    Tremblay AJ, Lamarche B, Ruel IL, Hogue JC, Deshaies Y, Gagné C, Couture P.
    Atherosclerosis; 2006 Sep 28; 188(1):203-12. PubMed ID: 16337207
    [Abstract] [Full Text] [Related]

  • 13. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
    Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T.
    J Lipid Res; 2004 Jan 28; 45(1):174-85. PubMed ID: 14523053
    [Abstract] [Full Text] [Related]

  • 14. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 28; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit.
    Carreón-Torres E, Juárez-Meavepeña M, Cardoso-Saldaña G, Gómez CH, Franco M, Fievet C, Luc G, Juárez-Oropeza MA, Pérez-Méndez O.
    Atherosclerosis; 2005 Aug 28; 181(2):233-40. PubMed ID: 16039276
    [Abstract] [Full Text] [Related]

  • 16. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine.
    Bolayirli IM, Aslan M, Balci H, Altug T, Hacibekiroglu M, Seven A.
    Life Sci; 2007 Jun 20; 81(2):121-7. PubMed ID: 17532348
    [Abstract] [Full Text] [Related]

  • 17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 20; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 18. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov 20; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G, Favari E, Calabresi L, Simonelli S, Bondioli A, Adorni MP, Zimetti F, Gomaraschi M, Coutant K, Rossomanno S, Niesor EJ, Bernini F, Benghozi R.
    J Clin Lipidol; 2013 Nov 20; 7(5):414-22. PubMed ID: 24079282
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.